MedTrace Logo

Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique

NCT05362682 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2023-04-19

No results posted yet for this study

Summary

Three complementary activities will be implemented:1) Baseline and repeat census of the catchment population; described in a separate protocol (IVI-ECOVA-03-WS1); 2) Enhanced surveillance for COVID-19 disease, and 3) AEFI-enhanced surveillance. The mass vaccination campaign will be conducted by the Government and is not part of this protocol.

Conditions

Interventions

OTHER

Sinopharm Vaccine

Sinopharm Vaccine will be administered by the Govt as part of COVID-19vaccination campaign

Sponsors & Collaborators

  • The Coalition for Epidemic Preparedness Innovations (CEPI)

    collaborator UNKNOWN

  • Instituto Nacional de Saúde, Mozambique

    collaborator OTHER_GOV

  • University of Antananarivo

    collaborator UNKNOWN

  • International Centre for Diarrhoeal Disease Research, Bangladesh

    collaborator OTHER

  • Harvard University

    collaborator OTHER

  • Heidelberg University

    collaborator OTHER

  • International Vaccine Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-24
Primary Completion
2024-02-28
Completion
2024-08-30

Countries

  • Mozambique

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05362682 on ClinicalTrials.gov